Novel antibody-drug conjugates
By introducing a new linker of polyethylene glycol unit into the antibody-drug conjugate, the problem of hydrophobic drug precipitation is solved, and the drug delivery efficiency and therapeutic effect are improved.
Patent Information
- Application Number
- CN202380034803.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-25
- Filing Date
- 2023-02-23
- Publication Date
- 2024-11-26
AI Technical Summary
Existing antibody-drug conjugates (ADCs) have insufficient performance in preventing hydrophobic drugs precipitation, which affects their therapeutic effect.
A novel linker containing polyethylene glycol units is used to form an antibody-drug conjugate (ADC) with excellent performance by binding to an antibody or fragment thereof to prevent drug precipitation and improve drug delivery efficiency.
Through the use of polyethylene glycol units, the physical properties of the antibody-drug conjugates are significantly improved, drug precipitation is prevented, drug delivery efficiency is enhanced, and therapeutic effect is improved.
Smart Images

Figure CN119031941A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a novel antibody-drug conjugate, and more particularly, to an antibody-drug conjugate comprising a polyethylene glycol unit, a solvate thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same. Background Art
[0002] Antibody-drug conjugates (ADCs) are compounds consisting of antibodies, drugs or payloads, and joints, and are prepared by covalently binding an antibody that binds to a specific target antigen to a drug that exhibits a pharmacological effect (e.g., apoptotic effect). ADCs require the ability to selectively recognize antigens or receptors, the ability to induce specific cell apoptosis, and the stability and dissociation of joints. Antibody-drug conjugates that meet these requirements can selectively act only on specific cells through targeting, thereby reducing side effects and increasing therapeutic effects. The research and development of antibody-drug conjugates is being advanced in various ways and is growing rapidly, and drug conjugates such as Adcetris, Kadcyla, Besponsa, Mylotarg, Polotuzumab, and Padcev have been approved by the FDA.
[0003] Polyethylene glycol (PEG) is a water-soluble, biocompatible and non-toxic polymer with ethylene oxide monomers as units. It is used to prolong plasma half-life, prevent enzyme degradation and provide sustained release through PEGylation in the pharmaceutical field. In the field of antibody-drug conjugates, attempts have also been made to use polyethylene glycol to provide beneficial effects. In this regard, a conjugate comprising PEG units is disclosed in U.S. Patent No. 11,103,593, and PEGylation for increasing anti-tumor activity and improving stability is disclosed. However, despite PEGylation, not all antibody-drug conjugates can improve drug properties, and the effect of the conjugate can vary according to joints, drugs, etc. Therefore, there is still a need for antibody-drug conjugates with high stability and improved physical properties.
[0004] Related technical literature
[0005] (Patent Document 1) U.S. Patent No. 1,110,359
[0006] (Non-patent Document 1) Construction of paclitaxel-based antibody-drug conjugates with a PEGylated linker to achieve superior therapeutic index, Ting Shao et al., Signal Transduction and Targeted Therapy 5, 2020
[0007] (Non-patent Document 2) Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates, Patrick J Burke et al., Mol Cancer Ther, 2017
[0008] (Non-patent document 3) An optimal "Click" formulation strategy for antibody-drug conjugate synthesis, Erol CVanserv et al., Bioorg Med Chem, 2020
[0009] (Non-patent document 4) Click Chemistry Conjugations, Tak IanChio et al., Methods Mol Biol, 2020 Summary of the invention
[0010] Technical issues
[0011] The present invention aims to provide a novel linker which can exhibit excellent performance and prevent the precipitation of hydrophobic drugs.
[0012] The present invention also aims to provide an antibody-drug conjugate (ADC) comprising the linker or a pharmaceutically acceptable salt thereof.
[0013] The present invention also aims to provide a pharmaceutical composition comprising the novel ADC.
[0014] Technical Solution
[0015] The present invention is described in detail below.
[0016] The present invention provides a conjugate represented by the following formula 1.
[0017] [Formula 1]
[0018]
[0019] in,
[0020] Ab is the ligand,
[0021] Sp1, Sp2, Sp3 and Sp4 are each independently a spacer group,
[0022] L1 is the first joint unit,
[0023] L2 is the second joint unit,
[0024] L3, L3' and L3" are each independently selected from a third linker unit,
[0025] X1, X2 and X3 are each independently selected from an active agent or a polyethylene glycol unit,
[0026] wherein at least one of X1, X2 and X3 is a polyethylene glycol unit,
[0027] z is an integer from 1 to 20,
[0028] n is an integer from 1 to 20,
[0029] m is an integer from 1 to 20,
[0030] When n and m are both greater than 2, L1, L2, L3, L3', Sp2, Sp3, X2 and X3 are each independently selected.
[0031] The present invention includes a conjugate or a solvate of a pharmaceutically acceptable salt thereof.
[0032] In one embodiment of the present invention, Ab is an antibody, an antibody fragment or an antigen-binding fragment thereof.
[0033] In the present invention, the antibody, antibody fragment or antigen-binding fragment thereof is a monoclonal antibody, a polyclonal antibody, an antibody fragment, Fab, Fab', F(ab)2, Fv, scFv, a diabody, a linear antibody, a bispecific antibody, a multispecific antibody, a chimeric antibody, a humanized antibody, a fully human antibody or an antigen-binding fragment thereof. In addition, in the present invention, the antibody, antibody fragment or antigen-binding fragment may comprise a light chain region (V L region), heavy chain region (V HRegion), their constant region or their variable region. In addition, the present invention includes variants of antibodies, wherein the ratio of one or more of the affinity / binding power / specificity / selectivity of the antibody is 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, or 97% or more.
[0034] Non-limiting examples of antibodies include IgA, IgG, IgG1, IgG2, IgG3, IgG4, IgE, and IgD in the present invention.
[0035] Non-limiting examples of antibodies of the present invention are as follows:
[0036] Anti-CD71 antibody, anti-EGFR antibody, anti-HER2 antibody, anti-CD20 antibody, anti-CA125 antibody, anti-CD19 antibody, anti-CD44 antibody, anti-CD22 antibody, anti-FAP antibody, anti-CD38 antibody, anti-CD56 antibody, anti-CEA antibody, anti-CD2 antibody, anti-CD3 antibody, anti-CD7 antibody, anti-CD10 antibody, anti-CD167 antibody, anti-CD140 antibody, anti-CD121 antibody, anti-CD145 antibody, anti-CD71 antibody, CCK2R, CLD18 (Clauin-18), CRIPTO, CSF2, CTLA4, DLL3, DLL4, interferon, interleukin (IL-1, IL-2, IL4, IL-9, etc.), IFN, NGF,
[0037] Cetuximab, panitumumab, nimotuzumab, brentuximab, rituximab, ofatumumab, tositumomab, ibrutinib, trastuzumab, pertuzumab, ozogamicin, ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, ciplizumab, sotuzumab, mepolizumab, motavizumab, motobizumab, natalizumab, nolovizumab, numavizumab, omalizumab, palivizumab, pascolizumab, pecfusituzumab, pectuzumab, pertuzumab, pexezumab, ranibizumab monoclonal antibody, reslivivsumab, reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab, tacatuzumab, tetraxetan, taduzumab, talizumab, tefibazumab, tocilizumab, toralizumab, trastuzumab, tucusituzumab, urtoxazumab, vislizumab, CNTO 95, huC242, and huN901.
[0038] In one embodiment of the present invention, the linker represented by a combination of some of Sp1, Sp2, Sp3, Sp4, L1, L2, L3, L3', L3", X1, X2 and X3 is a cleavable linker or a non-cleavable linker.
[0039] In one embodiment of the invention, the linker is a cleavable linker.
[0040] In one embodiment of the invention, the cleavable linker may be protease sensitive, pH sensitive or glutathione sensitive.
[0041] In one embodiment of the present invention, the linker can be an enzyme-cleavable linker. The linker that can be cleaved by the enzyme can contain one or more than two sites.
[0042] In an exemplary embodiment of the present invention, a linker represented by a combination of some of Sp1, Sp2, Sp3, Sp4, L1, L2, L3, L3', L3", X1, X2, and X3 is a cleavable linker that can be cleaved by glucuronidase. In addition, the linker is a linker that can be cleaved by β-glucuronidase.
[0043] In addition, in an exemplary embodiment of the present invention, a linker represented by a combination of some of Sp1, Sp2, Sp3, Sp4, L1, L2, L3, L3', L3", X1, X2 and X3 is a cleavable linker that can be cleaved by a cathepsin. For example, the linker may include a valine-citrulline (val-cit), a lysine-lysine (lys-lys), a phenylalanine-lysine (phen-lys), a valine-alanine (Val-Ala) or an alanine-alanine (Ala-Ala) linker, etc. In addition, the cleavable linker can be cleaved by a cathepsin and maintain a stable state in vivo. Furthermore, in a specific example, the cleavable linker can be cleaved by cathepsin B, cathepsin C or cathepsin D, and also maintains a stable state in vivo. Among these linkers, the valine-citrulline (Val-Cit) linker is a linker that can be cleaved by cathepsin B.
[0044] In addition, in the linker represented by a combination of some of Sp1, Sp2, Sp3, Sp4, L1, L2, L3, L3', L3", X1, X2 and X3 in the present invention, some of the spacer group, the first linker, the second linker and the third linker may be a unit that can be cleaved by a tissue protease (e.g., tissue protease B, C or D).
[0045] In one embodiment of the present invention, the linker may comprise a pH-sensitive linker comprising a group that induces hydrolysis of an acid-labile group (eg, a hydrazone).
[0046] In one embodiment of the invention, a glutathione-sensitive linker, such as a linker comprising a disulfide bond, may be included.
[0047] In the present invention, the antibody and the linker can be bound via the thiol of the antibody, especially the thiol of cysteine. In addition, in the present invention, the antibody and the linker can be bound via the amine of the antibody, especially the amine of lysine.
[0048] In the present invention, when antibodies are bound to the Linker unit, they may be bound via a structure including a spacer group.
[0049] In one embodiment of the present invention, the conjugate may include a structure bound by click chemistry. Specifically, the conjugate may include a structure bound by an oxime bond mediated by carbonyl-aminooxy or azide-alkyne click chemistry, or a structure bound by a previously known method (Bioorg Med Chem. 2020 Dec 15; 28 (24), Methods Mol Biol, 2020; 2078: 83-9, etc.).
[0050] In one embodiment of the present invention, the spacer group represents a direct bond or a chemical structure having 1 to 200 atoms.
[0051] In one embodiment of the present invention, the spacer group is one or more selected from the group consisting of a first spacer group, a second spacer group, a third spacer group and a fourth spacer group.
[0052] In one embodiment of the present invention, the spacer group is selected from two or more of the group consisting of a first spacer group, a second spacer group, a third spacer group and a fourth spacer group.
[0053] In one embodiment of the present invention, the spacer group is a combination of two or more selected from the group consisting of a first spacer group, a second spacer group, a third spacer group and a fourth spacer group.
[0054] In one embodiment of the present invention, the spacer group is a combination of a first spacer group, a second spacer group, a third spacer group and a fourth spacer group.
[0055] In one embodiment of the present invention, the first spacer group, the second spacer group, the third spacer group or the fourth spacer group are each independently selected from directly bonded, substituted or unsubstituted C 1-50 Alkylene, substituted or unsubstituted C 1-50 Heteroalkylene, substituted or unsubstituted C 2-50 Alkenylene, substituted or unsubstituted C 3-50 Cycloalkylene, substituted or unsubstituted C 6-50 Arylene and substituted or unsubstituted C 6-50 The group consisting of heteroarylene.
[0056] In one embodiment of the present invention, at least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is an unsubstituted C 1-10 Heteroalkylene.
[0057] In a specific embodiment of the present invention, at least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is an unsubstituted C 1-10 heteroalkylene, and contains an NH binding site.
[0058] In one embodiment of the present invention, at least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is a substituted C 1-20 Heteroalkylene,
[0059] Wherein, when the group is substituted, the group is selected from halogen, =O, OH, NH2, SH, NO2, N3, CN, OR1, SR1, OC(O)R1, OC(O)NHR1, OC(O)OR1, CONHR1, CON(R1)2, NHC(O)R1, C(O)R1, NHR1, N(R1)2, C(O)R1, OS(O)2R1, -OP(O)(OR1)(OR1), OP(O)(NHR1)(NHR1) and C 1-3 A substitution in the group consisting of alkyl,
[0060] Wherein, R1 is selected from H, OH, C 1-5 Alkyl, C 1-5 Heteroalkyl, C 3-8 Aryl and C 3-8 The group consisting of heteroaryl groups.
[0061] In one embodiment of the present invention, at least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is a substituted C 6-50 heteroarylene, wherein when the group is substituted, the group is selected from halogen, =O, OH, NH2, SH, NO2, N3, CN, OR1, SR1, OC(O)R1, OC(O)NHR1, OC(O)OR1, CONHR1, CON(R1)2, NHC(O)R1, C(O)R1, NHR1, N(R1)2, C(O)R1, OS(O)2R1, -OP(O)(OR1)(OR1), OP(O)(NHR1)(NHR1) and C 1-3 One substitution in the group consisting of alkylene,
[0062] Wherein, R1 is selected from H, OH, C 1-5 Alkyl, C 1-5 Heteroalkyl, C 3-8 Aryl and C 3-8 The group consisting of heteroaryl groups.
[0063] In an exemplary embodiment of the present invention, R1 is H, OH or C 1-3 alkyl.
[0064] In one embodiment of the present invention, at least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is C substituted by =O. 6-50 Heteroarylene.
[0065] In one embodiment of the present invention, at least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is directly bonded.
[0066] In one embodiment of the present invention, one or more of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group comprises a terminal C(O).
[0067] In one embodiment of the present invention, at least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group comprises a terminal NH.
[0068] In one embodiment of the present invention, one or more of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group comprises a terminal C(O)NH.
[0069] In one embodiment of the present invention, at least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is selected from -C(O)(CH2) a -、-NH(CH2) a -、-C(O)(CH2) a C(O)-, -C(O)(CH2) a NH-, -NH(CH2) a NH-、-NHC(O)(CH2) a C(O)-、-NHC(O)(CH2) a NH-、-NHC(O)(CH2) a C(O)NH- and -NHC(O)(CH2) a O(CH2) b - the group formed,
[0070] Here, a and b are each independently an integer of 1 to 10.
[0071] In an exemplary embodiment of the present invention, a and b are each independently an integer of 1-7.
[0072] In one embodiment of the present invention, at least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group comprises
[0073] In addition, in one embodiment of the present invention, one or more of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is
[0074] Wherein, X is substituted or unsubstituted C 1-10 Alkyl or substituted or unsubstituted C 1-10heteroalkyl, and when substituted, is substituted by one or more selected from the group consisting of halogen, =O, OH, NH2 and SH, and s1 is an integer of 1-10.
[0075] In one embodiment of the present invention, at least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is And s1 is an integer from 1 to 10.
[0076] In one embodiment of the present invention, at least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is
[0077] In one embodiment of the present invention, the spacer group is:
[0078] Among them, X a and X b are each independently substituted or unsubstituted C 1-10 Alkyl or substituted or unsubstituted C 1-10 and when the group is substituted, the group is substituted with one or more selected from the group consisting of halogen, =O, OH, NH2 and SH, and s1 is an integer of 1 to 10.
[0079] In one embodiment of the present invention, X a and X b Each independently selected from C(O)(CH2) a -、-NH(CH2) a -、-C(O)(CH2) a C(O)-, -C(O)(CH2) a NH-, -NH(CH2) a NH-、-NHC(O)(CH2) a C(O)-、-NHC(O)(CH2) a NH-、-NHC(O)(CH2) a C(O)NH- and -NHC(O)(CH2) a O(CH2) b - the group formed,
[0080] Here, a and b are each independently an integer of 1 to 10.
[0081] In one embodiment of the present invention, X a It is -C(O)-.
[0082] In one embodiment of the present invention, X bIt is -CH2C(O)- or -(CH2)2OCH2C(O)-NH-.
[0083] In one embodiment of the present invention, the spacer group is -NH-(CH2) a -NH-, and s is an integer of 1-5.
[0084] In one embodiment of the present invention, Sp1 is
[0085] X a of Bond to L1, and X b of bonded to Ab, and
[0086] Among them, X a , X b and s1 as described above.
[0087] In one embodiment of the present invention, L1 and L2 are each independently selected from the group consisting of a direct bond, an amino acid, an unnatural amino acid and derivatives thereof.
[0088] In one embodiment of the present invention, L1 and L2 are each independently selected from the group consisting of direct bonding, alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamate, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine and their derivatives.
[0089] In one embodiment of the present invention, L1 and L2 are each independently selected from the group consisting of direct bonding, arginine, asparagine, glutamic acid, glutamine, glycine, alanine, arginine, citrulline, isoleucine, leucine, lysine, phenylalanine, serine, tryptophan, valine and derivatives thereof.
[0090] In one embodiment of the present invention, L1 and L2 are each independently selected from the group consisting of direct bonding, arginine, asparagine, glutamic acid, glutamine, glycine, alanine, citrulline, lysine, phenylalanine, serine and valine.
[0091] In one embodiment of the present invention, L1 and L2 are each independently selected from the group consisting of direct bonding, arginine, asparagine, glutamine, citrulline, lysine, serine and valine.
[0092] In one embodiment of the present invention, L1 and L2 are each lysine.
[0093] In one embodiment of the present invention, L1 is * and ** are sites for binding to another L1 or to Sp1 or Sp4, and *** is a site for binding to L2.
[0094] In one embodiment of the present invention, one or more of L1 and L2 can be cleaved by an enzyme.
[0095] In one embodiment of the present invention, one or more of L1 and L2 can be cleaved by a tumor-associated protease.
[0096] In one embodiment of the present invention, at least one of L1 and L2 can be cleaved by glucuronidase. Specifically, at least one of L1 and L2 can be cleaved by β-glucuronidase.
[0097] In an exemplary embodiment of the invention, one or more of L1 and L2 can be cleaved by a cathepsin.
[0098] In one embodiment of the present invention, when L2 in the conjugate is directly bonded, -Sp2-L3-X2 or -Sp3-L3'-X3 is absent, and L1 is bonded to Sp2-L3-X2 or -Sp3-L3'-X3.
[0099] In one embodiment of the present invention, when all L2 are direct bonds, the conjugate can be represented by Formula 2 below.
[0100] [Formula 2]
[0101]
[0102] In the above formula,
[0103] Ab is the ligand,
[0104] Sp1, Sp2 and Sp4 are each independently a spacer group,
[0105] L1 is the first joint unit,
[0106] L3 and L3" are each independently selected from a third linker unit,
[0107] X1 and X2 are each independently selected from an active agent or a polyethylene glycol unit,
[0108] wherein at least one of X1 and X2 is a polyethylene glycol unit,
[0109] z is an integer from 1 to 20,
[0110] n is an integer from 1 to 20,
[0111] m is an integer from 1 to 20,
[0112] When n and m are 2 or more, L1, L3, Sp2 and X2 are each independently selected.
[0113] In addition, each spacer group, linker unit, active agent and polyethylene glycol unit herein are as defined above.
[0114] In one embodiment of the present invention, one or more of L3, L3' and L3" are direct bonds.
[0115] In one embodiment of the present invention, one or more of L3, L3′ and L3″ are represented by Formula A.
[0116] [Formula A]
[0117]
[0118] In the above formula,
[0119] G is glucuronic acid or its derivatives,
[0120] A1 and A2 are each independently selected from directly bonded, substituted or unsubstituted C 1-50 Alkylene, substituted or unsubstituted C 1-50 Heteroalkylene, substituted or unsubstituted C 2-50 Alkenylene, substituted or unsubstituted C 3-50 Cycloalkylene, substituted or unsubstituted C 6-50 Arylene and substituted or unsubstituted C 6-50 The group consisting of heteroarylene.
[0121] In one embodiment of the invention, G is β-glucuronic acid.
[0122] In one embodiment of the present invention, A1 is combined with X2 or X3.
[0123] In one embodiment of the invention, A2 is bound to Sp2, Sp3 or Sp4.
[0124] In one embodiment of the present invention, A1 is selected from -(CH2) a1 OC(O)-(CH2) b1 -、-(CH2) a1 C(O)-(CH2) b1 -、-(CH2) a1 NH-(CH2) b1 -、-(CH2) a1 C(O)NH-(CH2) b1 - and -(CH2) a1 OC(O)NH-(CH2)b1 - the group formed,
[0125] a1 and b1 are each independently an integer of 0-10.
[0126] In one embodiment of the present invention, A1 is -(CH2) a1 OC(O)-(CH2) b1 -, and a1 and b1 are each independently an integer of 0 to 5.
[0127] In one embodiment of the present invention, A1 is -CH2OC(O)-.
[0128] In one embodiment of the present invention, A2 is represented by formula A-1.
[0129] [Formula A-1]
[0130] -A 21 -A 22 -A 23 -
[0131] A 21 and A 23 Each independently selected from -O-, -OCO-, -OCOO-, -OCONR a -、-NHR a -、-NR a CO-、-NR a CONR b -、-NR a COO-、-NR a COR b -、-NR a CO-R b -CO-、-NR a CO-R b -NH- and S(O)-,
[0132] Among them, R a and R b Each independently is H or C 1-5 Alkylene, and
[0133] A 22 C 1-10 Alkylene or C 2-10 Alkenylene.
[0134] In one embodiment of the present invention, A2 is -NHC(O)-(CH2)2-NH-.
[0135] In the present invention, in the linker represented by a combination of some of Sp1, Sp2, Sp3, Sp4, L1, L2, L3, L3', L3", X1, X2 and X3, at least one of X1, X2 and X3 is a polyethylene glycol unit.
[0136] In the present invention, the polyethylene glycol units of the conjugate are combined in a parallel form of antibody-linker-drug, as represented in a combined form. In addition, in the present invention, more than two polyethylene glycol units may be included, which does not mean that all polyethylene glycol units are combined in a parallel form. However, the polyethylene glycol units of the present invention can be combined in a parallel form.
[0137] In one embodiment of the present invention, at least two or more of X1, X2 and X3 are polyethylene glycol repeating units.
[0138] In one embodiment of the present invention, the polyethylene glycol unit comprises -(CH2CH2O)- as a repeating unit.
[0139] In one embodiment of the present invention, the polyethylene glycol unit comprises -(CH2CH2O) x - as a repeating unit, and x is an integer of 4-40.
[0140] In one embodiment of the present invention, the polyethylene glycol unit comprises a -C(O)- binding site.
[0141] In one embodiment of the present invention, the polyethylene glycol unit comprises C 1-5 The terminal portion of an alkyl group.
[0142] In one embodiment of the present invention, the polyethylene glycol unit can be represented by the following formula:
[0143]
[0144] In the above formula, x is an integer of 4-40.
[0145] In one embodiment of the present invention, m is an integer less than n, and the m repeating units are each independently selected. In the present invention, the structural unit of m is combined with the structural unit of n, and the structural unit of m corresponds to an integer less than or equal to the structural unit of n.
[0146] In one embodiment of the present invention, n and m are both 1.
[0147] In one embodiment of the present invention, n and m are both integers greater than 2, in which case each structural unit can be independently selected from other structural units. For example, when n is 3, three L1s are included, and the three L1s can be independently selected from the group consisting of amino acids, non-natural amino acids and derivatives thereof to represent each L1. In addition, when m is 3, L2, Sp2, Sp3, L3', L3", X2 and X3 represent independently selected units, L2 can be independently selected from the group consisting of amino acids, non-natural amino acids and derivatives thereof to represent three different L1s, and the three X2 and X3 can be independently active agents or polyethylene glycol units.
[0148] In one embodiment of the present invention, n is an integer of 2-6.
[0149] In one embodiment of the present invention, n is an integer of 2-4.
[0150] In one embodiment of the present invention, m is an integer of 2-6.
[0151] In one embodiment of the present invention, m is an integer of 2-4.
[0152] In one embodiment of the present invention, at least one of X1, X2 and X3 is an active agent.
[0153] In the present invention, when L1 or L2 increases, the polyethylene glycol unit may increase. More specifically, when L1 or L2 increases by 1, the polyethylene glycol unit may increase by 1 or 2.
[0154] In a specific embodiment of the present invention, the conjugate may be a conjugate represented by the following formula 1-2.
[0155] [Formula 1-2]
[0156]
[0157] In the above formula, Ab, Sp1, X1 and z are the same as those defined in Formula 1,
[0158] L 11 , L 12 Same as the definition of L1 in Formula 1,
[0159] L 21 , L 22 Same as the definition of L2 in Formula 1,
[0160] L 31 , L 32 Same as the definition of L3 in Formula 1,
[0161] Sp 21 、Sp22 Same as the definition of Sp2 in Formula 1,
[0162] Sp 31 、Sp 32 Same as the definition of Sp3 in Formula 1,
[0163] X 21 , X 22 Same as the definition of X2 in Formula 1,
[0164] X 31 , X 32 The same definition as X3 in Formula 1.
[0165] Furthermore, in an exemplary embodiment of the present invention, the conjugate may be a conjugate represented by the following Formula 1-3.
[0166] [Formula 1-3]
[0167]
[0168] In the above formula, Ab, Sp1 and Sp4, L3", X1 and z are the same as those defined in Formula 1.
[0169] L 11 , L 12 Same as the definition of L1 in Formula 1,
[0170] L 21 , L 22 Same as the definition of L2 in Formula 1,
[0171] X 21 , X 22 Same as the definition of X2 in Formula 1,
[0172] X 31 , X 32 The same definition as X3 in Formula 1.
[0173] Furthermore, in a specific embodiment of the present invention, the conjugate may be a conjugate represented by the following formula 1-4.
[0174] [Formula 1-4]
[0175]
[0176] In the above formula, Ab, Sp1, Sp4, L3", X1 and z are the same as those in Formula 1.
[0177] L 11 Same as the definition of L1 in Formula 1,
[0178] L 21 Same as the definition of L2 in Formula 1,
[0179] X 21 Same as the definition of X2 in Formula 1,
[0180] X 31 The same definition as X3 in Formula 1.
[0181] In a specific embodiment of the present invention, the conjugate may be a conjugate represented by the following formula 1-5.
[0182] [Formula 1-5]
[0183]
[0184] In the above formula, Ab, Sp1, Sp4, L3", X1 and z are the same as those in Formula 1.
[0185] L 11 Same as the definition of L1 in Formula 1,
[0186] Sp 21 Same as the definition of Sp2 in Formula 1,
[0187] X 21 The same definition as X2 in Formula 1.
[0188] In one embodiment of the present invention, the conjugate may be a conjugate represented by Formula 1-6.
[0189] [Formula 1-6]
[0190]
[0191] In the above formula, Ab, Sp1, Sp4, L3", X1 and z are the same as those in Formula 1.
[0192] L 11 , L 12 Same as the definition of L1 in Formula 1,
[0193] L 22 Same as the definition of L2 in Formula 1,
[0194] L 32 Same as the definition of L3 in Formula 1,
[0195] Sp 22 Same as the definition of Sp2 in Formula 1,
[0196] X 21 , X 22 Same as the definition of X2 in Formula 1, and
[0197] X 32 The same definition as X3 in Formula 1.
[0198] Furthermore, the present invention relates to a linker unit represented by the following Formula 1a.
[0199] [Formula 1a]
[0200]
[0201] In the above formula,
[0202] Sp1, Sp2, Sp3 and Sp4 are each independently a spacer group,
[0203] L1 is the first joint unit,
[0204] L2 is the second joint unit,
[0205] At least one of X1*, X2* and X3* is a polyethylene glycol unit,
[0206] If one or more of X1*, X2* and X3* is not a polyethylene glycol unit, it is an active agent binding moiety,
[0207] n is an integer from 1 to 20,
[0208] m is an integer from 1 to 20,
[0209] Wherein, when n or m is 2 or more, L1, L2, L3, L3', Sp2, Sp3, X2* and X3* are each independently selected, and
[0210] Z is a ligand binding moiety.
[0211] In the present invention, L1, L2, Sp1, Sp2, Sp3 and Sp4 of Formula 1a are the same as defined in Formula 1.
[0212] Furthermore, in the present invention, when X1*, X2* and X3* of Formula 1a are not active agent binding moieties, they are defined the same as X1, X2 and X3 in Formula 1.
[0213] In one embodiment of the present invention, at least two of X1*, X2* and X3* are polyethylene glycol units.
[0214] In one embodiment of the invention, Z comprises an Fc binding protein.
[0215] In one embodiment of the present invention, Z is
[0216] Where X1 is CR, NR, S or O,
[0217] Where R is hydrogen, C 1-3 Alkyl, C 1-3 Heteroalkyl or C 1-3Alkoxy,
[0218] X2 is NH, and Z1 is an Fc binding protein.
[0219] In a specific embodiment of the present invention, Z1 is Ac-PEG8-DCAWH-(Dap)-GLVWCT-NH- (Ac: acetylation / Dap: diaminopropionic acid).
[0220] In one embodiment of the present invention, Z1 is Ac-PEG8-DCAWH-(Dap)-GELVWCT-NH- and contains a Cys-Cys disulfide bond (disulfide oxidation).
[0221] In one embodiment of the invention, the active agent binding moiety is absent or is selected from -(CH2) z1 OC(O)-(CH2) z2 -R z 、-(CH2) z1 C(O)-(CH2) z2 -R z 、-(CH2) z1 NH-(CH2) z2 -R z 、-(CH2) z1 C(O)NH-(CH2) z2 -R z 、-(CH2) z1 NHC(O)-(CH2) z2 -R z and -(CH2) z1 OC(O)NH-(CH2) z2 -R z The group composed of
[0222] Among them, R z COOH, NH2, C 2-5 Alkynyl, C 5-20 Cycloalkenyl, C 5-20 Cycloalkynyl, C 5-20 heterocycloalkynyl or N3, and
[0223] z1 and z2 are each independently an integer of 0-10.
[0224] In one embodiment of the invention, the active agent binding moiety is
[0225] Wherein, X3 is selected from -(CH2) z1 OC(O)-(CH2) z2 -R z 、-(CH2) z1C(O)-(CH2) z2 -R z 、-(CH2) z1 NH-(CH2) z2 -R z 、-(CH2) z1 C(O)NH-(CH2) z2 -R z 、-(CH2) z1 NHC(O)-(CH2) z2 -R z and -(CH2) z1 OC(O)NH-(CH2) z2 -R z The group composed of
[0226] Among them, R z COOH, NH2, C 2-5 Alkynyl, C 5-20 Cycloalkynyl, C 5-20 Heterocycloalkynyl or N3.
[0227] In one embodiment of the present invention, the active agent binding moiety is -C(O)-CH2-N3.
[0228] In an exemplary embodiment of the present invention, the linker unit may be a linker unit represented by the following Formula 1-2a.
[0229] [Formula 1-2a]
[0230]
[0231] In the above formula, Z and Sp1 are the same as in formula 1a,
[0232] L 11 , L 12 Same as L1 in formula 1a,
[0233] L 21 , L 22 Same as L2 in formula 1a,
[0234] Sp 21 、Sp 22 Same as Sp2 in Formula 1a,
[0235] X1*, X 21 *、X 22 *、X 31 * and X 32 *Each independently is a polyethylene glycol unit or an active agent binding moiety.
[0236] In one embodiment of the present invention, the linker unit may be a linker unit represented by Formula 1-3a.
[0237] [Formula 1-3a]
[0238]
[0239] In the above formula, Z, Sp1 and Sp4 are the same as those defined in Formula 1a,
[0240] L 11 , L 12 Same as L1 in formula 1a,
[0241] L 21 , L 22 Same as L2 in formula 1a,
[0242] X1*, X 21 *、X 22 *、X 31 * and X 32 *Each independently is a polyethylene glycol unit or an active agent binding moiety.
[0243] In a specific embodiment of the present invention, the linker unit may be a linker unit represented by the following formula 1-4a.
[0244] [Formula 1-4a]
[0245]
[0246] In the above formula, Z, Sp1 and Sp4 are the same as those defined in Formula 1a,
[0247] L 11 Same as L1 in formula 1a,
[0248] L 21 Same as L2 in formula 1a,
[0249] X1*, X 21 * and X 31 *Each independently is a polyethylene glycol unit or an active agent binding moiety.
[0250] In a specific embodiment of the present invention, the linker unit may be a linker unit represented by the following formula 1-5a.
[0251] [Formula 1-5a]
[0252]
[0253] In the above formula, Z, Sp1 and Sp4 are the same as those defined in Formula 1a,
[0254] L 11Same as L1 in formula 1a,
[0255] Sp 21 Same as Sp2 in Formula 1a,
[0256] X1* and X 21 *Each independently is a polyethylene glycol unit or an active agent binding moiety.
[0257] In an exemplary embodiment of the present invention, the linker unit may be a linker unit represented by the following Formula 1-6a.
[0258] [Formula 1-6a]
[0259]
[0260] In the above formula, Z, Sp1 and Sp4 are the same as those defined in Formula 1a,
[0261] L 11 and L 12 Same as L1 in formula 1a,
[0262] L 22 Same as L2 in formula 1a,
[0263] Sp 22 Same as Sp2 in Formula 1a,
[0264] X1*, X 21 *、X 22 * and X 32 *Each independently is a polyethylene glycol unit or an active agent binding moiety.
[0265] In one embodiment of the present invention, the active agent is selected from the group consisting of protein-targeted drugs, cell-targeted drugs, DNA-targeted drugs and RNA-targeted drugs.
[0266] In the present invention, "protein-targeted drugs", "cell-targeted drugs", "DNA-targeted drugs" and "RNA-targeted drugs" each refer to drugs that change or kill the function of any protein, cell, DNA or RNA in a harmful or harmless manner. More specifically, protein-targeted drugs, cell-targeted drugs, DNA-targeted drugs and RNA-targeted drugs can each be a toxic drug. "Toxic drugs" refer to drugs that change the function of any protein, cell, DNA or RNA in a harmful manner. For example, it can change cell growth, cell proliferation, protein synthesis and DNA synthesis in a harmful manner.
[0267] In the present invention, non-limiting examples of drugs are as follows:
[0268] Anti-tubulin agents, antibiotics, antifolates, alkylating agents, anthracyclines and camptothecins,
[0269] Specifically, cyclophosphamide, nitrogen mustard, chlorambucil, melphalan, carmustine (BCNU), lomustine (CCNU), ifofamine, procarbazine, dacarbazine, temozolomide, hexamethylmelamine, cisplatin, carboplatin, paclitaxel, taxotere, oxaliplatin, Aplysia 10, Aplysia 15, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), monomethyl auristatin D (MMAD), DM-1, DM-4, anthracycline, anti-tubulin agent, daunorubicin, doxorubicin, epirubicin, idarubicin, epirbucin, glarbuicin, daunomycin, actinomycin, bole mycobacterium, mitomycin, etoposide, valrubicin, mithramycin, mitoxantrone, paclitaxel, vincristine, vinblastine, vinorelbine, estramustine, nemorubicin, neocarcinostatin, docetaxel, puromycin, camptothecin, camtothecin, 10-hydroxycamptothecin, scutellarin, lortotecan, gimatecan, topotecan, irinotecan, exitecan, orathecin, pirarbucin, silatecan, cositecan, gimatecan, belotecan, rubitecan, SN-38, maytansine alkaloids, benzodiazepine Pyrrolobenzodiazepine Pyrrolobenzodiazepine dimer, calicheamicine, duocarmycin, methotrexate, amanitin, deoxycoformaycin, 6-mercaptopurine, 6-thioguanine, azathioprine, 2-chlorodeoxyadenosine, hydroxyurea, methotrexate, 5-fluorouracil, capecitabine, cytosine arabinoside, azacytidine, gemcitabine, fludarabine, asparaginase, FL118, afatinib.
[0270] In one embodiment of the invention, the active agent is an auristatin.
[0271] In an exemplary embodiment of the invention, the active agent is Aplysia, Afatinib, Duocarmycin, FL118, MMAD, MMAE or MMAF.
[0272] In one embodiment of the invention, the linker-active agent conjugated to the antibody is
[0273]
[0274]
[0275]
[0276] in,
[0277] BG-MMAE is as well as
[0278] m-PEG8 is
[0279] Furthermore, the present invention relates to a pharmaceutical composition comprising the combination.
[0280] In addition, the present invention relates to a pharmaceutical composition for preventing or treating a proliferative disease comprising the combination.
[0281] Furthermore, the present invention relates to a method for treating a proliferative disease, comprising administering a therapeutically effective amount of a composition comprising the conjugate to a subject in need of proliferative disease treatment.
[0282] Furthermore, the present invention relates to the use of a conjugate in the preparation of a medicament for treating a proliferative disease in a subject.
[0283] In one embodiment of the invention, the proliferative disease is cancer.
[0284] The administration route of the conjugate of the present invention can be, for example, oral or parenteral. Here, parenteral refers to the administration route in a broad sense, such as intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intranasal, sublingual, intracapsular, inhalation, ocular, rectal, vaginal, intraventricular administration, etc. When preparing the composition, it is formulated with commonly used diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants and surfactants.
[0285] Solid preparations for oral administration include tablets, pills, powders, granules and capsules, which are prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose, lactose or gelatin with the composition. In addition to simple excipients, lubricants such as magnesium stearate, talc, etc. are also used. Liquid preparations for oral administration include suspensions, liquids for internal administration, emulsions and syrups, and in addition to commonly used simple diluents such as water or liquid paraffin, various types of excipients such as wetting agents, sweeteners, spices and preservatives may also be included.
[0286] Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. As non-aqueous solvents or suspensions, propylene glycol, polyethylene glycol, vegetable oils (e.g. olive oil) or injectable esters (e.g. ethyl oleate) can be used. As suppository bases, Witepsol, Tween 61, cocoa butter, laurin butter, glycerol or gelatin can be used.
[0287] However, these are merely exemplary and are not limited thereto.
[0288] The composition of the present invention is administered in a pharmaceutically effective amount. "Pharmaceutically effective amount" as used herein refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio suitable for medical treatment, and an effective dose can be determined by including the patient's disease type, severity, drug activity, sensitivity to drugs, administration time, route of administration and excretion rate, duration of treatment and concurrently used drugs and other parameters known in the medical field. The composition of the present invention can be administered alone or in combination with other therapeutic agents, can be administered sequentially or simultaneously with conventional therapeutic agents, or administered in a single dose or multiple doses. Taking into account all of the above parameters, it is important to achieve maximum effect with a minimum dose without side effects, and such dosage can be easily determined by a person of ordinary skill in the art.
[0289] Beneficial Effects
[0290] The conjugate according to the present invention comprises a polyethylene glycol unit, and thus the conjugate can have excellent physical properties and prevent precipitation, thereby improving drug delivery efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0291] Figures 1 to 3 FIG. 4 is a schematic diagram showing a method for preparing a conjugate according to an embodiment of the present invention. DETAILED DESCRIPTION
[0292] In the present invention, each term is defined as follows.
[0293] In the present invention, "independently" means that one selection does not depend on or affect another selection, and thus each can be selected.
[0294] In the present invention, a "unit" refers to a unit that is segmented or can be segmented.
[0295] In the present invention, "analogs" and "derivatives" refer to compounds in which some parts are removed, modified or added from the parent compound.
[0296] In this specification, "linker" refers to the entire chemical part that connects a molecule or atom to another molecule (such as an antibody and an active agent). The linker may refer to a form in which multiple molecules or amino acids are combined through a chemical functional group that can be covalently bound.
[0297] In the present specification, "cleavable" has the same chemical / biological meaning as known in the art, including cleavage under specific conditions, such as acidic, reducing, enzymatic and the like conditions.
[0298] In this specification, "unsubstituted or substituted" means that the parent group can be unsubstituted or substituted, "substituted" means that the parent group has more than one substituent, and "substituent" refers to a chemical part covalently bonded or fused to the parent group.
[0299] In the present invention, "alkyl" is a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of an aliphatic or alicyclic, saturated or unsaturated (unsaturated, fully unsaturated) hydrocarbon compound, examples of saturated alkyl groups may include methyl, ethyl, propyl, butyl, pentyl, hexyl and heptyl, examples of saturated straight-chain alkyl groups may include methyl, ethyl, n-propyl, n-butyl, n-pentyl (pentyl), n-hexyl and n-heptyl, and examples of saturated branched-chain alkyl groups may include isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl and neopentyl.
[0300] In the present invention, "alkenyl" is an alkyl group having one or more carbon-carbon double bonds, and examples of unsaturated alkenyl groups may include ethenyl (vinyl, -CH=CH2), 1-propenyl (-CH=CHCH3), 2-propenyl, isopropenyl, butenyl, pentenyl and hexenyl.
[0301] In the present invention, "alkynyl group" is an alkyl group having one or more carbon-carbon triple bonds, and examples of the unsaturated alkynyl group may include ethynyl and 2-propynyl.
[0302] In the present invention, the "alkylene group" refers to a divalent moiety obtained by further removing one hydrogen atom from a carbon atom in an alkyl group.
[0303] In the present invention, the "alkenylene group" refers to a divalent moiety obtained by further removing one hydrogen atom from a carbon atom in an alkenyl group.
[0304] In the present invention, the "alkynylene group" refers to a divalent moiety obtained by further removing one hydrogen atom from a carbon atom in an alkynyl group.
[0305] In the present invention, "halogen" means fluorine, chlorine, bromine or iodine.
[0306] In the present invention, "aryl" is a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound.5-7 "Aryl" refers to a monovalent moiety having 5 to 7 ring atoms obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, "C 5-10 "Aryl" refers to a monovalent moiety having 5 to 10 ring atoms obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound. Here, the prefix (C 5-7 , C 5-10 etc.) refers to the number of ring atoms or ranges of ring atoms, regardless of whether they are carbon atoms or heteroatoms. For example, "C 5-6 "Aryl" refers to an aromatic group having 5 or 6 ring atoms. Here, the ring atoms may all be carbon atoms, as in "carboaryl". Examples of carboaryl groups include carboaryl groups derived from benzene, naphthalene, azulene, anthracene, phenanthrene, tetracene and pyrene, but the present invention is not limited thereto. Examples of aryl groups containing fused rings (at least one of which is aromatic) include groups derived from indane, indene, isoindene, tetralin, acenaphthene, fluorene, phenalene, acephenanthrene and acetanthracene, but the present invention is not limited thereto. Alternatively, the ring atoms may contain more than one heteroatom, as in "heteroaryl".
[0307] In the present invention, "heteroaryl" refers to an aromatic group containing one or more heteroatoms, and may include, for example, pyridine, pyrimidine, benzothiophene, furanyl, dioxolane, pyrrolyl, oxazolyl, pyridyl, pyridazinyl and pyrimidinyl, more specifically, C9 has a moiety derived from benzofuran, isobenzofuran, indole, isoindole, indolizine, indoline, isoindolinol, purine (adenine or guanine), benzimidazole, indazole, benzofuran, isobenzofuran, indole, isoindole, indole, indoline, isoindolinol, purine (adenine or guanine), benzimidazole, indazole, benzofuran, isobenzofuran, indole, isoindolinol ... azole, benzyl isocyanate Azoles, benzophenone Two fused rings of benzofuran, benzotriazole, benzothiophene, benzothiazole and benzothiadiazole; C 10 Derived from chromene, isochromene, chroman, isochromene, benzodioxane, quinoline, isoquinoline, quinolizine, benzo Two fused rings of oxazine, benzodiazine, pyridopyridine, quinoxaline, quinazoline, cinnoline, phthalazine, naphthyridine and pteridine; C 11 Benzodiazepine Induced two fused rings; C 13 Derived from carbazole, dibenzofuran, dibenzothiophene, carboline, three fused rings of pyridine and pyridoindole; and C 14 Derived from acridine, xanthene, thioxanthene, xanthene, phen Thiamine, phenazine, phen The three fused rings of oxazine, phenothiazine, thioxanthene, phenanthridine, phenanthroline and phenazine.
[0308] In the present invention, "cycloalkyl" is a cyclic alkyl group, which refers to a monovalent part obtained by removing a hydrogen atom from an alicyclic atom of a cyclic hydrocarbon compound. Examples of cycloalkyl groups include the following compounds and derivatives thereof, but the present invention is not limited thereto. "Cycloalkyl" may include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, methylcyclopropane, dimethylcyclopropane, methylcyclobutane, dimethylcyclobutane, methylcyclopentane, dimethylcyclopentane and methylcycloheptane; unsaturated monocyclic hydrocarbon compounds such as cyclopropene, cyclobutene, cyclopentene, cyclohexene, methylcyclopropene, dimethylcyclopropene, methylcyclobutene, dimethylcyclobutene, methylcyclopentene, dimethylcyclopentene and methylcyclohexene; and saturated heterocyclic hydrocarbon compounds such as norcarane, norpinane and norbornane.
[0309] In the present invention, the "arylene group" refers to a divalent moiety obtained by further removing one hydrogen atom from a carbon atom in an aryl group.
[0310] In the present invention, the "heteroarylene group" refers to a divalent moiety obtained by further removing one hydrogen atom from a carbon atom in a heteroaryl group.
[0311] In the present invention, the prefix (for example, C 1-12 , C 3-8 , etc.) refers to the number of ring atoms or the range of the number of ring atoms, regardless of whether it is a carbon atom or a heteroatom. For example, the term "C 3-6 The term "heterocyclic group" refers to a heterocyclic group having 3 to 6 ring atoms, and here, the types of the ring atoms are not limited thereto.
[0312] In the present invention, "solvate" refers to a molecular complex between a compound according to the present invention and a solvent molecule, and examples of solvates include a compound according to the present invention in combination with water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, ethanolamine or a mixed solvent thereof, but the present invention is not limited thereto.
[0313] In the present invention, "pharmaceutically acceptable salt" refers to a salt form of the compound of the present invention having the desired pharmacological activity. Salt forms include inorganic acids (hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid) and organic acids (acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid and benzoic acid), but the present invention is not limited thereto.
[0314] In the present invention, "pharmaceutically effective amount" refers to an amount sufficient to prevent or treat a disease at a reasonable benefit / risk ratio applicable to medical prevention or treatment, and the effective dose can be determined by parameters including the severity of the disease, drug activity, patient weight, health, gender and drug sensitivity, administration time, route and excretion rate of the composition of the present application used herein, duration of treatment and drugs used in combination or concomitantly with the composition of the present application used herein, as well as other parameters well known in the medical field.
[0315] The present invention can improve drug properties by arranging specific units in parallel in antibody-drug conjugates.
[0316] The present invention can be designed to achieve effective release of active compounds by binding to specific amino acid positions of the antibody Fc domain, and the linker and active agent moieties can be controlled to bind to specific amino acid positions.
[0317] In order to control the orientation and binding position of the polyethylene glycol unit, a suitable joint or functional group can be introduced, and accordingly, the selectivity, pharmacokinetics, etc. of the antibody-drug conjugate can be different. Specifically, in order to control the parallel orientation and binding position of the polyethylene glycol unit, a compound containing an amino acid or an amine functional group with an amine functional group can be used. The polyethylene glycol unit can be increased or decreased according to the number of amino acids with an amine functional group. In addition, the polyethylene glycol unit can be increased or decreased according to the position and structure of the amino acid with an amine functional group.
[0318] In the present invention, the parallel orientation of the polyethylene glycol units can shield or mask the hydrophobic portion of the drug, thereby enabling the drug to be efficiently released in the target cells. Therefore, an enhancement effect such as PK enhancement and improved in vivo efficacy is shown. The polyethylene glycol units can be used in a position or amount suitable for shielding or masking the hydrophobic portion of the drug, which can vary depending on the type of drug.
[0319] In a specific embodiment, a thioester functional group can be introduced to achieve binding to the Fc domain of IgG1, IgG3 or IgG4 antibody 248. In addition, to increase reactivity, a compound containing a maleimide functional group or a thiol-reactive additive compound can be used.
[0320] In a specific embodiment, in order to remove interfering factors (e.g., hydrogen bonds that may be generated when the cyclic peptide binds to the antibody), a C6 spacer group (e.g., a C6 alkyl structure) may be introduced and combined with lysine at amino acid position 248. In addition, after the functional group is introduced by introducing a spacer group at amino acid position 248, a drug may be introduced, thereby exhibiting a three-dimensional shielding or shielding effect.
[0321] In a specific embodiment, the amino acid having an amine functional group may be lysine. However, this is only an example that can be realized, and the present invention is not limited thereto.
[0322] The present invention is described in detail below with reference to embodiments and experimental examples.
[0323] However, the following Examples and Experimental Examples are only illustrative, and the contents of the present invention are not limited to the following Examples and Experimental Examples.
[0324] [Example]
[0325] <Example 1-1> Preparation of linker (PEG BRNAched payload linker)
[0326]
[0327] Preparation of compound 1
[0328] 50 mL of dichloromethane was added to 2 g of 2-chlorotrityl chloride resin (1.4 mmol / g) and then stirred for 30 minutes. Subsequently, ethylenediamine (5.6 mmol, 2 equivalents) and N, N'-diisopropylethylamine (11.2 mmol, 4 equivalents) were mixed with 40 mL of dichloromethane and then added to the resin. After the resulting mixture was stirred at room temperature for 2 hours, the reaction solution was removed. Then, 50 mL of dichloromethane and 50 mL of dimethylformamide were added three times to wash the remaining resin, thereby preparing compound 1.
[0329] Preparation of compound 2
[0330] N-α-Fmoc-N-ε-[1-(4,4-dimethyl-2,6-dioxycyclohex-1-ylidene)ethyl]-L-lysine (5.6mmol, 2 equivalents), hydroxybenzotriazole (11.2mmol, 4 equivalents) and N,N'-diisopropylcarbodiimide (5.6mmol, 2 equivalents) were added to the resin containing compound 1, and the resulting mixture was stirred at room temperature for 2 hours by using 50mL of dimethylformamide as a solvent, and then the reaction solution was removed. Subsequently, the amino acid N-α-Fmoc-N-ε-[1-(4,4-dimethyl-2,6-dioxycyclohex-1-ylidene)ethyl]-L-lysine and 4,7,10,13,16,19,22,25-octaoxacohexadecanoic acid were added in sequence, and the process was repeated in the same manner as above. After the reaction of 4,7,10,13,16,19,22,25-octaoxahexaconic acid, 50 mL each of dichloromethane and dimethylformamide were added three times to wash the resin, thereby preparing Compound 2.
[0331]
[0332] Preparation of compound 3
[0333] After 50 mL of 5% (volume ratio) hydrazine-containing dimethylformamide was added to the resin and stirred at room temperature for 10 minutes, the reaction solution was removed. Subsequently, 50 mL each of dichloromethane and dimethylformamide were added three times to wash the resin, thereby preparing Compound 3.
[0334] Preparation of compound 4
[0335] N-α-Fmoc-N-ε-[1-(4,4-dimethyl-2,6-dioxocyclohexane-1-ylidene)ethyl]-L-lysine (11.2mmol, 4 equivalents), hydroxybenzotriazole (22.4mmol, 8 equivalents) and N,N'-diisopropylcarbodiimide (11.2mmol, 4 equivalents) were added to the resin containing compound 3, and the resulting mixture was stirred at room temperature for 2 hours using 50mL of dimethylformamide as a solvent, and then the reaction solution was removed. After the reaction, 40mL of a 20% (volume ratio) dimethylformamide solution containing piperidine was added to the resin and stirred at room temperature for 10 minutes, and then the solution was removed (repeated twice). Then, 50mL of dichloromethane and dimethylformamide were added three times to wash the resin. For the next reaction, succinic anhydride (16.8mmol, 6 equivalents) was added, diisopropylethylamine (16.8mmol, 6 equivalents) was added to the resin, and then 50mL of dimethylformamide was added as a solvent, stirred at room temperature for 1 hour, and then the reaction solution was removed. After the reaction was completed, 50mL of dichloromethane and dimethylformamide were added three times for washing. The following steps were the same as those for preparing compound 3. Subsequently, 2,5,8,11,14,17,20,23-octaoxacohexadecane-26-acid (28mmol, 2 equivalents), hydroxybenzotriazole (56mmol, 4 equivalents) and N,N'-diisopropylcarbodiimide (28mmol, 2 equivalents) were added in sequence, 50mL of dimethylformamide was added as a solvent, the reaction activation treatment was carried out for 10 minutes, and then the resulting product was added to the resin. After stirring at room temperature for 2 hours, the reaction solution was removed. After the reaction was completed, 50 mL each of dichloromethane and dimethylformamide were added three times to wash the obtained product, and then the resin was dried to prepare Compound 4.
[0336]
[0337] Preparation of compound 5
[0338] 50mL of trifluoroacetic acid (TFA), triisopropylsilane (TIS) and deionized water (DW) were mixed in a volume ratio of 95:2.5:2.5 (TFA:TIS:DW), and the resin treated until compound 4 was prepared was added, and then stirred at room temperature for 2 hours. After stirring, the solution and the resin were separated, 500mL of diethyl ether at 0°C was added to the separated solution, then mixed, and the resulting mixture was placed at 0°C for more than 2 hours. After filtering the precipitated product, 50mL of diethyl ether at 0°C was added and filtered again (repeated twice). Then, the obtained product was dried to prepare compound 5 (2.24mmol, 80%).
[0339] Preparation of compound 6
[0340] Compound 5 (1 g, 0.511 mmol) and (2,5-dioxo-1-pyrrolidinyl 11,12-dihydro-ε-oxodibenzo[b,f]azepine-5(6)-hexanoate (DBCO-C6-NHS; 0.613 mmol, 1.2 equiv) were mixed in 10 mL of dimethylformamide, and diisopropylethylamine (1.022 mmol, 2 equiv) was added to the resulting mixture, and stirred at room temperature for 1 hour. After the reaction was completed, trifluoroacetic acid was added until the pH of the solution reached 5.0. The reaction solution was purified by preparative HPLC (C18) to obtain compound 6 (0.434 mmol, 85%).
[0341]
[0342] Preparation of compound 7
[0343] Compound 6 (0.434mmol) and tetramethyl-O-(N-succinimidyl) urea tetrafluoroborate (1.736mmol, 4 equivalents) were mixed with 10mL dimethylformamide, diisopropylethylamine (1.736mmol, 4 equivalents) was added, and the resulting mixture was stirred at room temperature for 0.5 to 2 hours. After the reaction was completed, trifluoroacetic acid was added until the pH of the solution reached 5.0. The reaction solution was purified by preparative HPLC (C18) and freeze-dried to obtain compound 7.
[0344] Preparation of compound 8
[0345] After the prepared H2N-BG-MMAE (0.26mmol, 1.2 equivalents) was mixed with the synthesized compound 7 (0.217mmol) in 5mL dimethylformamide, diisopropylethylamine (0.434mmol, 2 equivalents) was added, and the resulting mixture was stirred at room temperature for 1 hour. After the reaction was completed, trifluoroacetic acid was added until the pH of the solution reached 5.0. The reaction solution was purified by preparative HPLC (C18), freeze-dried, thereby obtaining compound 8. Compound 8 was dried, sealed, and then stored at -80°C.
[0346] <Example 1-2> Preparation of NH2-β-glucuronide-monomethyl auristatin E (NH2-BG-MMAE)
[0347]
[0348] Reagents and conditions: (9) Ag2O, molecular sieves, ACN; (10) NaBH4, IPA / DCM; (11) H2, Pd / C, EA, EtOH, MeOH;
[0349] (12) Fmoc-β-alanine chloride, DIPEA, DCM; (13) bis-(4-nitrophenyl) carbonate, DIPEA, THF;
[0350] (14)MMAE, DMAP, HOBt, DIPEA, DMF; (15)LiOH, MeOH / H2O Preparation of compound 9
[0351] 4-Hydroxy-3-nitrobenzaldehyde (4 g, 29.6 mmol) was dissolved in 120 mL of acetonitrile, and then molecular sieves (10 g) were added. Then, acetyl bromide-α-D-glucuronic acid methyl ether (10.3 g, 32.6 mmol) and silver (I) oxide (7 g, 30.2 mmol) were added and stirred for 18 hours under an argon atmosphere. The reaction solution was filtered through diatomaceous earth, concentrated under reduced pressure, and the organic layer was extracted with ethyl acetate and distilled water. The collected organic layer was dried over anhydrous magnesium sulfate. After filtration, it was concentrated and purified by column chromatography to obtain compound 9 (12.6 g, 88%).
[0352] Preparation of compound 10
[0353] After compound 9 (12.6 g, 26.0 mmol) was dissolved in isopropanol (50.6 mL) and chloroform (185 mL), sodium borohydride (1.67 g, 44.1 mmol) was slowly added at 0°C under a nitrogen atmosphere, and then stirred for 2.5 hours. Deionized water was added to the reaction solution and stirred for 15 minutes. Ethyl acetate and deionized water were added to extract the organic layer. The collected organic layer was dried over anhydrous magnesium sulfate. After filtration, it was concentrated and purified by column chromatography to obtain compound 10 (7.7 g, 61.1%).
[0354] Preparation of compound 11
[0355] After compound 10 (6.7 g, 14.2 mmol) was dissolved in ethyl acetate (90 mL), ethanol (190 mL) and methanol (44 mL), palladium (0.33 g) was added and stirred for 3 hours in a hydrogen atmosphere. The reaction solution was filtered through celite, concentrated under reduced pressure, and then purified by column chromatography to obtain compound 11 (5.3 g, 76.9%).
[0356] Preparation of compound 12
[0357] Fluorenylmethoxycarbonyl-β-alanine (Fmoc-β-alanine) (2.46 g, 7.9 mmol) was dissolved in dichloromethane (13 mL) and N,N-dimethylformamide (0.5 mL), and oxalyl chloride (1.36 mL, 15.8 mmol) was slowly added under a nitrogen atmosphere, and the resulting mixture was stirred for 2 hours. After the reaction solution was concentrated under reduced pressure, the concentrate was slowly added to compound 3 (3 g, 6.59 mmol) dissolved in dichloromethane (33 mL) at 0°C. Diisopropylethylamine (2.68 mL, 7.9 mmol) was slowly added to the dissolved compound at 0°C. After the reaction solution was concentrated, it was purified by column chromatography to obtain compound 12 (3.9 g, 79.1%).
[0358] Preparation of compound 13
[0359] After dissolving compound 12 (2.5 g, 3.34 mmol) in dichloromethane (30 mL), bis(4-nitrophenyl) carbonate (1.73 g, 5.7 mmol) and N,N-diisopropylethylamine (0.99 mL, 5.68 mmol) were added and stirred for 2 hours. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound 13 (2.3 g, 75.4%).
[0360] Preparation of compound 14
[0361] After dissolving compound 13 (1 g, 1.09 mmol) in N,N-diisopropylethylamine (10.8 mL), monomethyl auristatin E (MMAE, 0.864 g, 1.2 mmol), N-hydroxybenzotriazole hydrate (HOBt.H2O, 0.44 g, 3.27 mmol) and N,N-diisopropylethylamine (0.28 mL, 1.64 mmol), the resulting mixture was stirred at room temperature for 18 hours. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound 14 (1.45 g, 89%).
[0362] Preparation of compound 15
[0363] After dissolving compound 14 (1.4 g, 9.37 mmol) in methanol (15.2 mL), 0.4 N lithium hydroxide solution (1.5 mL) was added to the resulting mixture, followed by stirring for 6 hours. The reaction solution was purified by column chromatography to obtain compound 15 (0.62 g, 59%).
[0364] <Example 2-1> Preparation of linker (C6PEG3 linker)
[0365]
[0366] Preparation of compound 1
[0367] 50mL of dichloromethane was added to 5g of 2-chlorotrityl chloride resin (1.4mmol / g). Then stirred for 30 minutes. After stirring, the solvent was removed and the next step of reaction was carried out. Fmoc-L-6-aminocaproic acid (14mmol, 2 equivalents) and N, N'-diisopropylethylamine (28mmol, 4 equivalents) were mixed with 40mL of dichloromethane and then added to the resin. After stirring at room temperature for 2 hours, the reaction solution was removed. Subsequently, 50mL of dichloromethane and 50mL of dimethylformamide were added three times, the remaining resin was washed, and compound 1 was prepared.
[0368] Preparation of compound 2
[0369] 40 mL of a 20% (volume ratio) piperidine-containing dimethylformamide solution was added to the resin and stirred at room temperature for 10 minutes, and then the reaction solution was removed (repeated twice). Then, the remaining resin was washed by adding 20 mL of dichloromethane and 20 mL of dimethylformamide three times. N-α-Fmoc-N-ε-[1-(4,4-dimethyl-2,6-dioxocyclohexane-1-ylidene)ethyl]-L-lysine (14 mmol, 2 equivalents), hydroxybenzotriazole (28 mmol, 4 equivalents) and N,N'-diisopropylcarbodiimide (14 mmol, 2 equivalents) used in the following reaction were added to the resin, and 50 mL of dimethylformamide was used as a solvent to stir the resulting product at room temperature for 2 hours, and then the reaction solution was removed. Subsequently, the above process was repeated in the same manner as above by sequentially adding N-α-Fmoc-N-ε-[1-(4,4-dimethyl-2,6-dioxacyclohexane-1-ylidene)ethyl]-L-lysine and 4,7,10,13,16,19,22,25-octaoxacosanoic acid. After the reaction of 4,7,10,13,16,19,22,25-octaoxacosanoic acid, 50 mL of dichloromethane and 50 mL of dimethylformamide were added three times to wash the resin, thereby preparing compound 2.
[0370]
[0371] Preparation of compound 3
[0372] After 50 mL of 5% (volume ratio) hydrazine-containing dimethylformamide was added to the resin and stirred at room temperature for 10 minutes, the reaction solution was removed. Then, 50 mL of dichloromethane and 50 mL of dimethylformamide were added three times to wash the remaining resin, thereby preparing Compound 3.
[0373] Preparation of compound 4
[0374] N-α-Fmoc-N-ε-[1-(4,4-dimethyl-2,6-dioxacyclohexane-1-ylidene)ethyl]-L-lysine (28 mmol, 4 equivalents), hydroxybenzotriazole (56 mmol, 8 equivalents) and N,N'-diisopropylcarbodiimide (28 mmol, 4 equivalents) were added to the resin, 50 mL of dimethylformamide was added as a solvent, stirred at room temperature for 2 hours, and then the reaction solution was removed. After the reaction, 40 mL of a 20% (volume ratio) piperidine-containing dimethylformamide solution was added to the resin, stirred at room temperature for 10 minutes, and then the reaction solution was removed (repeated twice). Subsequently, 50 mL of dichloromethane and 50 mL of dimethylformamide were added three times to wash the resin. For the following reaction, after 2-azidoacetic acid (28mmol, 2 equivalents), hydroxybenzotriazole (56mmol, 4 equivalents) and N, N'-diisopropylcarbodiimide (28mmol, 2 equivalents) were added to the resin, 50mL of dimethylformamide was added as a solvent, stirred at room temperature for 2 hours, and the solution was removed. After the reaction was completed, 50mL of dichloromethane and 50mL of dimethylformamide were added three times to wash. The next step was the same as the above-mentioned step for preparing compound 3, 2,5,8,11,14,17,20,23-octaoxacohexadecane-26-acid (28mmol, 2 equivalents), hydroxybenzotriazole (56mmol, 4 equivalents) and N, N'-diisopropylcarbodiimide (28mmol, 2 equivalents) were added in sequence, 50mL of dimethylformamide was added as a solvent, stirred at room temperature for 2 hours, and then the solution was removed. After the reaction was completed, 50 mL of dichloromethane and 50 mL of dimethylformamide were added three times, the resin was washed, and the resin was dried to prepare Compound 4.
[0375]
[0376] Preparation of compound 5
[0377] 50mL trifluoroacetic acid (TFA), triisopropylsilane (TIS) and deionized water (DW) were mixed in a volume ratio of 95:2.5:2.5 (TFA:TIS:DW), added to the resin treated until compound 4 was prepared, and the resulting mixture was stirred at room temperature for 2 hours. After stirring, the solution and the resin were separated. 500mL of 0°C ether was added to the separated solution and mixed, and then placed at 0°C for more than 2 hours. After filtering the precipitated product, 50mL of 0°C diethyl ether was added and then filtered (repeated twice). Subsequently, the obtained product was dried to prepare compound 5 (5.11mmol, 73%).
[0378] Preparation of compound 6
[0379] Compound 5 (0.996 g, 0.5 mmol) and tetramethyl-O-(N-succinimidyl) urea tetrafluoroborate (1 mmol, 2 equivalents) were mixed with 5 mL of dimethylformamide, N, N'-diisopropylethylamine (1.5 mmol, 3 equivalents) was added, and the resulting mixture was stirred at room temperature for 1 hour. After the reaction was completed, trifluoroacetic acid was added until the pH of the solution reached 4.0. The reaction solution was purified by preparative HPLC (C18) to obtain compound 6 (0.375 mmol, 75%).
[0380] Preparation of compound 7
[0381] Compound 6 (0.375mmol) and tert-butyl 2-mercaptoacetate (0.7mmol, 2 equivalents) were added to 5mL dimethylformamide, N,N'-diisopropylethylamine (1.1mmol, 3 equivalents) was added, and the resulting mixture was stirred at room temperature for 1 hour. After the reaction was completed, trifluoroacetic acid was added until the pH of the solution reached 4.0. The reaction solution was purified by preparative HPLC (C18) and freeze-dried to obtain compound 7 (0.3mmol, 80%).
[0382] Preparation of compound 8
[0383] 10 mL of trifluoroacetic acid and dichloromethane were mixed in a volume ratio of 1:1, added to compound 7 (0.375 mmol), and then stirred at room temperature for 1 hour. After the reaction was completed, the solution was removed with a vacuum concentrator, and 10 mL of dichloromethane was added to perform reduced pressure concentration (repeated three times), thereby obtaining compound 8. Compound 8 was dried and stored at -80°C (0.297 mmol, 99%).
[0384] Preparation of compound 9
[0385] 10mL dimethylformamide solution was added to compound 8 (0.375mmol). N, N'-diisopropylethylamine was added to adjust the pH to 8-9. After the resulting mixture was stirred at room temperature for 10 minutes, tetramethyl-O-(N-succinimidyl) urea tetrafluoroborate (0.7mmol, 2 equivalents) and N, N'-diisopropylethylamine (0.375mmol, 1 equivalent) were subsequently added and stirred at room temperature for 2 hours. After the reaction was completed, trifluoroacetic acid was added until the pH of the solution reached 4.0. The reaction solution was purified by preparative HPLC (C18) and freeze-dried to obtain compound 9 (0.173mmol, 46%).
[0386] Preparation of compound 10
[0387] 5 mL of dimethylformamide solution was added to compound 9 (0.173 mmol), FcBP (sequence: Ac-PEG8-DCAH-(Dap)-GLVWCT-NH2, Fc-binding peptide, L-type amino acid, disulfide bond) (0.225 mmol, 1.2 equivalents) peptide complex synthesized by solid phase peptide synthesis (SPPS) was added, N, N'-diisopropylethylamine (0.26 mmol, 1.5 equivalents) was added, and the mixture was reacted at room temperature for 1 hour. After the reaction was completed, the obtained product was purified by preparative HPLC (C18) and freeze-dried to obtain compound 10 (348 mg, 0.087 mmol, 50%).
[0388] <Example 2-2> Preparation of linker (C6PEG4 linker)
[0389]
[0390] Preparation of compound 11
[0391] Compound 11 was synthesized by solid phase synthesis. 50 mL of dichloromethane was added to 2 g of 2-chlorotrityl chloride resin (1.4 mmol / g) and stirred for 30 minutes. After stirring, the solvent was removed, and Fmoc-L-6-aminocaproic acid (5.6 mmol, 2 equivalents) and N, N'-diisopropylethylamine (11.2 mmol, 4 equivalents) were mixed with 40 mL of dichloromethane and then added to the resin. After stirring at room temperature for 2 hours, the reaction solution was removed. Then, 50 mL of dichloromethane and 50 mL of dimethylformamide were added three times, and the remaining resin was washed to prepare compound 11.
[0392] Preparation of compound 12
[0393] 40 mL of a 20% (volume ratio) piperidine-containing dimethylformamide solution was added to the resin and stirred at room temperature for 10 minutes, and then the reaction solution was removed (repeated twice). Then, 20 mL of dichloromethane and 20 mL of dimethylformamide were added three times to wash the remaining resin. N-α-Fmoc-N-ε-[1-(4,4-dimethyl-2,6-dioxocyclohexane-1-ylidene)ethyl]-L-lysine (5.6 mmol, 2 equivalents), hydroxybenzotriazole (11.2 mmol, 4 equivalents) and N,N'-diisopropylcarbodiimide (5.6 mmol, 2 equivalents) used in the next reaction were added to the resin, 50 mL of dimethylformamide was added as a solvent, stirred at room temperature for 2 hours, and then the reaction solution was removed. Then, the process was repeated in the same manner by sequentially adding N-α-Fmoc-N-ε-[1-(4,4-dimethyl-2,6-dioxacyclohexane-1-ylidene)ethyl]-L-lysine and 2-azidoacetic acid. After the reaction of 2-azidoacetic acid, 50 mL of dichloromethane and 50 mL of dimethylformamide were added three times to wash the resin, thereby preparing Compound 12.
[0394]
[0395] Preparation of compound 13
[0396] 50 mL of 5% (volume ratio) hydrazine-containing dimethylformamide was added to the resin, stirred at room temperature for 10 minutes, and then the reaction solution was removed. Then, 50 mL of dichloromethane and 50 mL of dimethylformamide were added three times to wash the resin, thereby preparing Compound 13.
[0397] Preparation of compound 14
[0398] N-α-Fmoc-N-ε-Fmoc-L-lysine (11.2 mmol, 4 equivalents), hydroxybenzotriazole (22.4 mmol, 8 equivalents) and N,N'-diisopropylcarbodiimide (11.2 mmol, 4 equivalents) were added to the resin, 50 mL of dimethylformamide was added as a solvent, stirred at room temperature for 2 hours, and then the reaction solution was removed. After the reaction, 40 mL of a 20% (volume ratio) dimethylformamide solution containing piperidine was added to the resin, stirred at room temperature for 10 minutes, and then the solution was removed (repeated twice). Then, 50 mL of dichloromethane and 50 mL of dimethylformamide were added three times to wash the resin. Next, 4,7,10,13,16,19,22,25-octaoxaconic acid (22.4 mmol, 8 equivalents) was added, and then hydroxybenzotriazole (44.8 mmol, 16 equivalents) and N,N'-diisopropylcarbodiimide (22.4 mmol, 8 equivalents) were added to the resin in the same manner as the above method, 50 mL of dimethylformamide was added as a solvent and stirred at room temperature for 2 hours, and then the reaction solution was removed. After the reaction was completed, 50 mL of dichloromethane and 50 mL of dimethylformamide were added three times, the remaining resin was washed, and then the obtained resin was dried to prepare compound 14.
[0399]
[0400] Preparation of compound 15
[0401] 50mL trifluoroacetic acid (TFA), triisopropylsilane (TIS) and deionized water (DW) were mixed in a volume ratio of 95:2.5:2.5 (TFA:TIS:DW), added to the resin treated until compound 14 was prepared, and then stirred at room temperature for 2 hours. After stirring, the solution and the resin were separated. 500mL of 0°C diethyl ether was added to the separated solution and mixed, and then allowed to stand for more than 2 hours. After filtering the precipitated product, 50mL of 0°C diethyl ether was added and then filtered again (repeated twice). Then, the obtained product was dried to prepare compound 15 (2.13mmol, 76%).
[0402] Preparation of compound 16
[0403] Compound 15 (1 g, 0.433 mmol) and tetramethyl-O-(N-succinimidyl) urea tetrafluoroborate (1 mmol, 2 equivalents) were added to 5 mL of dimethylformamide, followed by N,N'-diisopropylethylamine (1.3 mmol, 3 equivalents) and stirred at room temperature for 1 hour. After the reaction was complete, trifluoroacetic acid was added until the pH of the solution reached 4.0. The reaction solution was purified by preparative HPLC (C18) to give compound 16 (0.303 mmol, 70%).
[0404] Preparation of compound 17
[0405] Compound 16 (0.303mmol) and tert-butyl 2-mercaptoacetate (0.606mmol, 2 equivalents) were added to 5mL dimethylformamide, and then N, N'-diisopropylethylamine (0.909mmol, 3 equivalents) was added and stirred at room temperature for 1 hour. After the reaction was completed, trifluoroacetic acid was added until the pH of the solution reached 4.0. The reaction solution was purified by preparative HPLC (C18) and freeze-dried to obtain compound 17 (0.242mmol, 80%).
[0406] Preparation of compound 18
[0407] 10 mL of trifluoroacetic acid and dichloromethane were mixed in a 1:1 volume ratio, added to compound 17 (0.242 mmol), and then stirred at room temperature for 1 hour. After the reaction was completed, the solution was removed with a vacuum concentrator, and 10 mL of dichloromethane was added, and the mixture was concentrated under reduced pressure (repeated three times) to prepare compound 18. Compound 18 was dried and stored at -80 ° C.
[0408] Preparation of compound 19
[0409] 10 mL of dimethylformamide solution was added to compound 18 (0.242 mmol), N, N'-diisopropylethylamine was added, and the pH was adjusted to 8-9. After the resulting mixture was stirred at room temperature for 10 minutes, tetramethyl-O-(N-succinimidyl) urea tetrafluoroborate (0.7 mmol, 2 equivalents) was added, N, N'-diisopropylethylamine (0.375 mmol, 1 equivalent) was added and stirred at room temperature for 2 hours. After the reaction was completed, trifluoroacetic acid was added until the pH of the solution reached 4.0. The reaction solution was purified by preparative HPLC (C18) and freeze-dried to obtain compound 19 (0.124 mmol, 51%).
[0410] Preparation of compound 20
[0411] 5 mL of dimethylformamide solution was added to compound 19 (0.173 mmol), and then FcBP (sequence: Ac-PEG8-DCAWH-(Dap)-GELVWCT-NH2, Fc-binding peptide, L-type amino acid, disulfide bond) (0.225 mmol, 1.2 equivalents) peptide complex synthesized by solid phase peptide synthesis (SPPS) was added, and N, N'-diisopropylethylamine (0.26 mmol, 1.5 equivalents) was added to react at room temperature for 1 hour. After the reaction was completed, the obtained product was purified by preparative HPLC (C18) and freeze-dried to obtain compound 20 (283 mg, 0.066 mmol, 53%).
Claims
1. A conjugate represented by the following formula 1: [Formula 1] in, Ab is the ligand, Sp1, Sp2, Sp3 and Sp4 are each independently a spacer group, L1 is the first joint unit, L2 is the second joint unit, L3, L3' and L3" are each independently selected from a third linker unit, X1, X2 and X3 are each independently selected from an active agent or a polyethylene glycol unit, wherein at least one of X1, X2 and X3 is a polyethylene glycol repeating unit, z is an integer from 1 to 20, n is an integer from 1 to 20, m is an integer from 1 to 20, When n and m are 2 or more, L1, L2, L3, L3', Sp2, Sp3, X2 and X3 are each independently selected.
2. The conjugate according to claim 1, wherein Ab is an antibody, an antibody fragment, or an antigen-binding fragment thereof.
3. The conjugate according to claim 1, wherein The spacer group is one or more selected from a first spacer group, a second spacer group, a third spacer group and a fourth spacer group.
4. The conjugate according to claim 1, wherein The spacer group is selected from two or more of a first spacer group, a second spacer group, a third spacer group and a fourth spacer group.
5. The conjugate according to claim 3, wherein The first spacer group, the second spacer group, the third spacer group and the fourth spacer group are each independently selected from directly bonded, substituted or unsubstituted C 1-50 Alkylene, substituted or unsubstituted C 1-50 Heteroalkylene, substituted or unsubstituted C 2-50 Alkenylene, substituted or unsubstituted C 3-50 Cycloalkylene, substituted or unsubstituted C 6-50 Arylene and substituted or unsubstituted C 6-50 The group consisting of heteroarylene.
6. The conjugate according to claim 3, wherein At least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is an unsubstituted C 1-10 Heteroalkylene.
7. The conjugate according to claim 3, wherein At least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is a substituted C 1-20 Heteroalkylene, Wherein, when the group is substituted, the group is selected from halogen, =O, OH, NH2, SH, NO2, N3, CN, OR1, SR1, OC(O)R1, OC(O)NHR1, OC(O)OR1, CONHR1, CON(R1)2, NHC(O)R1, C(O)R1, NHR1, N(R1)2, C(O)R1, OS(O)2R1, -OP(O)(OR1)(OR1), OP(O)(NHR1)(NHR1) and C 1-3 A substitution in the group consisting of alkyl, Wherein, R1 is selected from H, OH, C 1-5 Alkyl, C 1-5 Heteroalkyl, C 3-8 Aryl and C 3-8 The group consisting of heteroaryl groups.
8. The conjugate according to claim 3, wherein At least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is a substituted C 6-50 Heteroarylene, Wherein, when the group is substituted, the group is selected from halogen, =O, OH, NH2, SH, NO2, N3, CN, OR1, SR1, OC(O)R1, OC(O)NHR1, OC(O)OR1, CONHR1, CON(R1)2, NHC(O)R1, C(O)R1, NHR1, N(R1)2, C(O)R1, OS(O)2R1, -OP(O)(OR1)(OR1), OP(O)(NHR1)(NHR1) and C 1-3 One substitution in the group consisting of alkylene, Wherein, R1 is selected from H, OH, C 1-5 Alkyl, C 1-5 Heteroalkyl, C 3-8 Aryl, C 3-8 The group consisting of heteroaryl groups.
9. The conjugate according to claim 3, wherein One or more of the first spacer group, the second spacer group, and the third spacer group are directly bonded.
10. The conjugate according to claim 3, wherein One or more of the first spacer group, the second spacer group, the third spacer group, and the fourth spacer group comprises a terminal C(O).
11. The conjugate according to claim 3, wherein At least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is selected from -C(O)(CH2) a -、-NH(CH2) a -、-C(O)(CH2) a C(O)-, -C(O)(CH2) a NH-, -NH(CH2) a NH-、-NHC(O)(CH2) a C(O)-、-NHC(O)(CH2) a NH-、-NHC(O)(CH2) a C(O)NH- and -NHC(O)(CH2) a O(CH2) b - the group formed, Here, a and b are each independently an integer of 1 to 10.
12. The conjugate according to claim 3, wherein One or more spacer groups are 13. The conjugate according to claim 1, wherein L1 and L2 are each independently selected from the group consisting of a direct bond, an amino acid, an unnatural amino acid, and derivatives thereof.
14. The conjugate according to claim 1, wherein L1 and L2 are each independently selected from the group consisting of direct bonding, alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamate, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine and derivatives thereof.
15. The conjugate according to claim 1, wherein L1 and L2 are each independently selected from the group consisting of direct bonding, alanine, arginine, citrulline, isoleucine, leucine, lysine, phenylalanine, tryptophan, valine and derivatives thereof.
16. The conjugate according to claim 1, wherein L1 and L2 are each independently selected from the group consisting of a direct bond, alanine, citrulline, lysine, phenylalanine and valine.
17. The conjugate according to claim 1, wherein One or more of L1 and L2 are cleavable by a tumor-associated protease.
18. The conjugate according to claim 1, wherein One or more of L1 and L2 are cleavable by β-glucuronidase.
19. The conjugate according to claim 1, wherein L3, L3' and L3" are each independently directly bonded or represented by the following formula A: [Formula A] in, G is glucuronic acid or its derivatives, A1 and A2 are each independently selected from directly bonded, substituted or unsubstituted C 1-50 Alkylene, substituted or unsubstituted C 1-50 Heteroalkylene, substituted or unsubstituted C 2-50 Alkenylene, substituted or unsubstituted C 3-50 Cycloalkylene, substituted or unsubstituted C 6-50 Arylene and substituted or unsubstituted C 6-50 The group consisting of heteroarylene.
20. The conjugate according to claim 19, wherein G is β-glucuronic acid.
21. The conjugate according to claim 19, wherein A1 is combined with X2 or X3.
22. The conjugate according to claim 19, wherein A2 binds to Sp2, Sp3 or Sp4.
23. The conjugate according to claim 19, wherein A1 is selected from -(CH2) a1 OC(O)-(CH2) b1 -、-(CH2) a1 C(O)-(CH2) b1 -、-(CH2) a1 NH-(CH2) b1 -、-(CH2) a1 C(O)NH-(CH2) b1 - and -(CH2) a1 OC(O)NH-(CH2) b1 - the group formed, Here, a1 and b1 are each independently an integer of 0 to 10.
24. The conjugate according to claim 19, wherein A1 is -(CH2) a1 OC(O)-(CH2) b1 -, wherein a1 and b1 are each independently an integer of 0 to 5.
25. The conjugate according to claim 19, wherein A2 is represented by formula A-1: [Formula A-1] -A 21 -A 22 -A 23 - Among them, A 21 and A 23 Each independently selected from -O-, -OCO-, -OCOO-, -OCONR a -、-NHR a -、-NR a CO-、-NR a CONR b -、-NR a COO-、-NR a COR b -、-NR a CO-R b -CO-、-NR a CO-R b The group consisting of -NH- and -S(O)-, Among them, R a and R b Each independently is H or C 1-5 alkyl, Among them, A 22 C 1-10 Alkylene or C 2-10 Alkenylene.
26. The conjugate according to claim 19, wherein A2 is -NHC(O)-(CH2)2-NH-.
27. The conjugate according to claim 1, wherein At least two or more of X1, X2 and X3 are polyethylene glycol units.
28. The conjugate according to claim 1, wherein The polyethylene glycol unit contains -(CH2CH2O)- as a repeating unit.
29. The conjugate according to claim 1, wherein The polyethylene glycol unit comprises -(CH2CH2O) x - as a repeating unit, wherein x is an integer of 4 to 40.
30. The conjugate according to claim 1, wherein The polyethylene glycol unit also contains a -C(O)- binding moiety.
31. The conjugate according to claim 1, wherein The polyethylene glycol unit also comprises C 1-5 The terminal portion of an alkyl group.
32. The conjugate according to claim 1, wherein m is an integer equal to or less than n, and the m repeating units are each independently selected.
33. The conjugate according to claim 1, wherein At least one of X1, X2 and X3 is the active agent.
34. The conjugate according to claim 1, wherein The active agent is selected from the group consisting of protein-targeted drugs, cell-targeted drugs, DNA-targeted drugs and RNA-targeted drugs.
35. The conjugate according to claim 1, wherein The linker-active agent other than Ab of Formula 1 is in, BG-MMAE is m-PEG8 is 36. A pharmaceutical composition for preventing or treating a proliferative disease, comprising the conjugate according to any one of claims 1 to 35.
37. A linker unit represented by the following formula 1a: [Formula 1a] in, Sp1, Sp2, Sp3 and Sp4 are each independently a spacer group, L1 is the first joint unit, L2 is the second joint unit, L3, L3' and L3" are independently selected third linker units, At least one of X1*, X2* and X3* is a polyethylene glycol unit, If one or more of X1*, X2* and X3* is not a polyethylene glycol unit, it is an active agent binding moiety, and n is an integer from 1 to 20, m is an integer from 1 to 20, Wherein, when n or m is 2 or more, L1, L2, L3, L3', Sp2, Sp3, X2* and X3* are each independently selected, Z is a ligand binding moiety.
38. The joint unit according to claim 37, wherein The spacer group is any one or more selected from the group consisting of a first spacer group, a second spacer group, a third spacer group and a fourth spacer group.
39. The joint unit according to claim 37, wherein The spacer group is any two or more selected from the group consisting of a first spacer group, a second spacer group, a third spacer group and a fourth spacer group.
40. The joint unit according to claim 38, wherein The first spacer group, the second spacer group, the third spacer group or the fourth spacer group are independently selected from directly bonded, substituted or unsubstituted C 1-50 Alkylene, substituted or unsubstituted C 1-50 Heteroalkylene, substituted or unsubstituted C 2-50 Alkenylene, substituted or unsubstituted C 3-50 Cycloalkylene, substituted or unsubstituted C 6-50 Arylene, substituted or unsubstituted C 6-50 The group consisting of heteroarylene.
41. The joint unit according to claim 38, wherein At least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is an unsubstituted C 1-10 Heteroalkylene.
42. The joint unit according to claim 38, wherein At least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is a substituted C 1-20 Heteroalkylene, Wherein, when the group is substituted, the group is selected from halogen, =O, OH, NH2, SH, NO2, N3, CN, OR1, SR1, OC(O)R1, OC(O)NHR1, OC(O)OR1, CONHR1, CON(R1)2, NHC(O)R1, C(O)R1, NHR1, N(R1)2, C(O)R1, OS(O)2R1, -OP(O)(OR1)(OR1), OP(O)(NHR1)(NHR1) and C 1-3 A substitution in the group consisting of alkyl, Wherein, R1 is selected from H, OH, C 1-5 Alkyl, C 1-5 Heteroalkyl, C 3-8 Aryl and C 3-8 The group consisting of heteroaryl groups.
43. The joint unit according to claim 38, wherein At least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is a substituted C 6-50 Heteroarylene, Wherein, when the group is substituted, the group is selected from halogen, =O, OH, NH2, SH, NO2, N3, CN, OR1, SR1, OC(O)R1, OC(O)NHR1, OC(O)OR1, CONHR1, CON(R1)2, NHC(O)R1, C(O)R1, NHR1, N(R1)2, C(O)R1, OS(O)2R1, -OP(O)(OR1)(OR1), OP(O)(NHR1)(NHR1) and C 1-3 One substitution in the group consisting of alkylene, Wherein, R1 is selected from H, OH, C 1-5 Alkyl, C 1-5 Heteroalkyl, C 3-8 Aryl and C 3-8 The group consisting of heteroaryl groups.
44. The joint unit according to claim 38, wherein One or more of the first spacer group, the second spacer group, the third spacer group, and the fourth spacer group are directly bonded.
45. The joint unit according to claim 38, wherein One or more of the first spacer group, the second spacer group, the third spacer group, and the fourth spacer group comprises a terminal C(O).
46. The joint unit according to claim 38, wherein At least one of the first spacer group, the second spacer group, the third spacer group and the fourth spacer group is selected from -C(O)(CH2) a -、-NH(CH2) a -、-C(O)(CH2) a C(O)-, -C(O)(CH2) a NH-, -NH(CH2) a NH-、-NHC(O)(CH2) a C(O)-、-NHC(O)(CH2) a NH-、-NHC(O)(CH2) a C(O)NH- and -NHC(O)(CH2) a O(CH2) b - the group formed, Here, a and b are each independently an integer of 1 to 10.
47. The joint unit according to claim 37, wherein L1 and L2 are each independently selected from the group consisting of a direct bond, an amino acid, an unnatural amino acid, and derivatives thereof.
48. The joint unit according to claim 37, wherein L1 and L2 are each independently selected from the group consisting of direct bonding, alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamate, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine and derivatives thereof.
49. The joint unit according to claim 37, wherein L1 and L2 are each independently selected from the group consisting of direct bonding, alanine, arginine, citrulline, isoleucine, leucine, lysine, phenylalanine, tryptophan, valine and derivatives thereof.
50. The joint unit according to claim 37, wherein L1 and L2 are each independently selected from the group consisting of a direct bond, alanine, citrulline, lysine, phenylalanine and valine.
51. The joint unit according to claim 37, wherein One or more of L1 and L2 are cleavable by tumor-associated proteases.
52. The joint unit according to claim 37, wherein One or more of L1 and L2 may be cleavable by β-glucuronidase.
53. The joint unit according to claim 37, wherein: L3, L3' and L3" are each independently a direct bond, or represented by the following formula A: [Formula A] in, G is glucuronic acid or its derivatives, A1 and A2 are each independently selected from directly bonded, substituted or unsubstituted C 1-50 Alkylene, substituted or unsubstituted C 1-50 Heteroalkylene, substituted or unsubstituted C 2-50 Alkenylene, substituted or unsubstituted C 3-50 Cycloalkylene, substituted or unsubstituted C 6-50 Arylene and substituted or unsubstituted C 6-50 The group consisting of heteroarylene.
54. The joint unit according to claim 53, wherein G is β-glucuronic acid.
55. The joint unit according to claim 53, wherein A1 is combined with X2 or X3.
56. The joint unit according to claim 53, wherein A2 binds to Sp2, Sp3 or Sp4.
57. The joint unit according to claim 53, wherein A1 is selected from -(CH2) a1 OC(O)-(CH2) b1 -、-(CH2) a1 C(O)-(CH2) b1 -、-(CH2) a1 NH-(CH2) b1 -、-(CH2) a1 C(O)NH-(CH2) b1 - and -(CH2) a1 OC(O)NH-(CH2) b1 - the group formed, Here, a1 and b1 are each independently an integer of 0 to 10.
58. The joint unit according to claim 53, wherein A1 is -(CH2) a1 OC(O)-(CH2) b1 -, wherein a1 and b1 are each independently an integer of 0 to 5.
59. The joint unit according to claim 53, wherein A2 is represented by the following formula A-1: [Formula A-1] -A 21 -A 22 -A 23 - Among them, A 21 and A 23 Each independently selected from -O-, -OCO-, -OCOO-, -OCONR a -、-NHR a -、-NR a CO-、-NR a CONR b -、-NR a COO-、-NR a COR b -、-NR a CO-R b -CO-、-NR a CO-R b The group consisting of -NH- and -S(O)-, Among them, R a and R b Each independently is H or C 1-5 alkyl, Among them, A 22 C 1-10 Alkylene or C 2-10 Alkenylene.
60. The joint unit according to claim 53, wherein A2 is -NHC(O)-(CH2)2-NH-.
61. The joint unit according to claim 37, wherein Two or more of X1*, X2* and X3* are polyethylene glycol units.
62. The joint unit according to claim 37, wherein The polyethylene glycol unit contains -(CH2CH2O)- as a repeating unit.
63. The joint unit according to claim 37, wherein The polyethylene glycol unit comprises -(CH2CH2O) x - as a repeating unit, wherein x is an integer of 4 to 40.
64. The joint unit according to claim 37, wherein The polyethylene glycol unit also contains a -C(O)- binding moiety.
65. The joint unit according to claim 37, wherein The polyethylene glycol unit also comprises C 1-5 The terminal portion of an alkyl group.
66. The connector unit according to claim 37, wherein m is an integer equal to or less than n, and the m repeating units are each independently selected.
67. A method for treating a proliferative disease comprising administering to a subject in need of treatment a therapeutically effective amount of a composition comprising the conjugate of any one of claims 1-35.
68. Use of the conjugate according to any one of claims 1 to 35 for the preparation of a medicament for the treatment of a proliferative disease.
